Physician profile
Gerald G Lim
NPI 1407819014
$1,707.55
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $230 · 2021: $383 · 2022: $295 · 2023: $220 · 2024: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $360.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $459.26 | 2019-2024 | |
| Pfizer INC. | $197.65 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $197.57 | 2019-2022 | |
| Allergan, INC. | $143.23 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $122.14 | 2019-2022 | |
| W. L. Gore & Associates, INC. | $118.59 | 2019 | |
| Abbvie INC. | $115.62 | 2021-2024 | |
| Gilead Sciences, INC. | $103.74 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $66.01 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $60.87 | 2021-2024 | Lifevest |
| Chiesi USA, INC. | $21.07 | 2022 | |
| Melinta Therapeutics, LLC | $19.01 | 2020 | |
| Vifor Pharma, INC. | $18.80 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.18 | 2023 | Jardiance |
| Shire North American Group INC | $16.42 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $15.86 | 2023 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.